Following the first Phase 3 study of HyBryte(TM) for the treatment of CTCL, the FDA and the EMA indicated that they would require a second successful Phase 3 trial to support mark ...

FLASH2 study  Blinded Response Rate to Date Exceeds Trial Estimate PRINCETON, N.J., Nov. 19, 2025 /PRNewswire/ -- ...

New research links cat exposure to doubled risk of developing schizophrenia A surprising new meta-analysis is stirring fresh debate about the link ...

FLASH2 study Blinded Response Rate to Date Exceeds Trial Estimate PRINCETON, N.J., Nov. 19, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix ...

The Princess of Wales has made her first public appearance since announcing her cancer diagnosis in March. Labour’s health ...